The main findings from the pooled analyses were as follows: (1) PFS was better in patients receiving PD-1/PD-L1, especially within the subgroup of patients with dMMR; (2) OS showed a significant difference favoring PD-1/PD-L1 group beyond 18 months in dMMR subgroup, while no difference was observed for patients with pMMR; and (3) adverse effects such as nausea, rash, fatigue, peripheral neuropathy, constipation, diarrhea, dyspnea, anemia, neutropenia, arthralgia, and hypothyroidism were noted in both treatment groups. This evidence concerns the gene PDCD1 and Decreased total neutrophil count.